American Home Products
Maryland U.S. Attorney is investigating Wyeth-Ayerst's "adverse events reporting system and the reporting of adverse events related to Redux and Pondimin," AHP discloses in Securities & Exchange Commission filing. AHP "is in the process of responding to the subpoena and continues to believe that its conduct with respect to the diet drugs has at all times been lawful and appropriate"
You may also be interested in...
Wyeth-Ayerst has been working on process improvements at its Marietta, Penn. plant for six months, the company said following a June 15 seizure action filed by FDA against products produced at the facility.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011